VCEL

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 1999, for Aastrom Biosciences, Inc. (Note: The input metadata referenced "Vericel Corp," but the filing text explicitly identifies the registrant as Aastrom Biosciences, Inc.). The company is in the development stage, focusing on research and product development for the ex vivo production of human cells for cell and gene therapy. Its lead product candidate is the AastromReplicell(TM) Cell Production System. The company has commenced an initial product launch in Europe but does not expect to generate positive cash flows from operations for at least the next several years.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased to $251,000 for the quarter and $621,000 for the nine months ended March 31, 1999, compared to $80,000 and $145,000 in the same periods of 1998. This increase is attributed to higher research activities under grants.
• Expense Reduction: Total costs and expenses decreased to $3,674,000 for the quarter and $11,279,000 for the nine months, down from $5,688,000 and $14,215,000 in 1998. This was driven primarily by a reduction in Research and Development (R&D) expenses.
• Improved Net Loss: The net loss narrowed to $3,307,000 for the quarter (from $5,355,000) and $8,945,000 for the nine months (from $13,388,000). The nine-month 1999 loss included a one-time gain of $1,237,000 from the termination of a marketing agreement with Cobe.
• Liquidity Position: Combined cash, cash equivalents, and short-term investments totaled $7,435,000 at March 31, 1999, a decrease of $3,777,000 from June 30, 1998, due to operational cash usage.

Guidance, Outlook, and Risks

• Outlook: Management does not expect positive cash flow from operations for at least the next several years. The company anticipates that available cash resources will fund operations into late-1999, pending additional funding.
• Capital Needs: The company intends to seek additional funding through collaborative arrangements, grants, or public/private financing. Failure to secure adequate funds could force the delay or termination of R&D programs.
• Regulatory and Clinical Risks: Commercialization depends on FDA approval for U.S. sales and CE Mark compliance for Europe. Clinical trials involve risks of patient complications or death, and there is no assurance of successful regulatory approval.
• Strategic Changes: The company terminated its distribution agreement with Cobe BCT, Inc. in November 1998 to consolidate marketing rights. It is seeking a new marketing partner.
• Unusual Items: A $1,100,000 charge was recorded in R&D expenses for the issuance of common stock to Immunex Corporation as payment for a license renewal fee. Additionally, a $1,237,000 one-time gain was recognized from the Cobe agreement termination.
• Year 2000 Issues: The company believes its systems are compliant but faces uncertainty regarding supplier compliance, which could impact operations.

Investor Verification Checklist

• Verify the company's ability to secure additional funding before late-1999 to sustain operations and clinical trials.
• Monitor the status of U.S. pivotal clinical trials and the timeline for FDA clearance.
• Assess the progress in securing a new marketing and distribution partner following the termination of the Cobe agreement.
• Review the terms of the 1998 Series I Convertible Preferred Stock, including the potential for conversion into common stock and the conditions for the Series II Preferred Stock purchase.
• Confirm the company's compliance with European Medical Device Directives (MDD) and the maintenance of the CE Mark.